Q-omics provides the consensus-scored ZNF584 profile across patient tissues and cancer cell-line models. ZNF584 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ZNF584 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, ZNF584 RNA expression shows 19,672 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, COAD, and ACC as cancer lineages where ZNF584 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF584 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF584 survival associations across molecular data types. ZNF584 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF584 RNA expression–survival associations across cancer types. High ZNF584 expression shows unfavorable associations in MESO, ACC, LGG and BLCA, but favorable associations in BRCA and UCEC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ZNF584 RNA expression.
This table summarizes ZNF584 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF584. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF584 shows lower tumor expression in KICH and higher tumor expression in COAD, LIHC, KIRP, CHOL and HNSC. The COAD box plot shows higher ZNF584 RNA expression in tumor versus normal tissue (log2 FC = +0.759, t-test p < 0.001).
This table shows molecular features associated with ZNF584 in patient tissues and cancer cell lines. In patient samples, ZNF584 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF584 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
